11–20 of 1001 posts
UK already ordered 30M out of the 50M avail for this year. So no going on winter break to Thailand just yet! Wondering who will grab the next 20M, and how much this vaccine is being sold per dose. (edit: PFE is currently trading +13% pre-market on the NYSE)
UK already ordered 30M out of the 50M avail for this year. So no going on winter break to Thailand just yet! Wondering who will grab the next 20M, and how much this vaccine is being sold per dose. (edit: PFE is currently trading +13% pre-market on the NYSE)
https://www.fiercepharma.com/pharma/pfizer-biontech-s-u-s-su...
At the time of writing (2020-11-09 12:04 UTC) the article uses "90% of people" and "90% protection" interchangeably. I assume it means "90% of individuals achieve immunity", rather than "individuals achieve 90% immunity". EDIT: See child comment re: Pfizer press release. EDIT 2: See [1] for said press release, which has more detailed information than the BBC article. [1] https://investors.pfizer.com/investor-news/pre…
From Pfizer's press release, they use "vaccine efficacy" which has a very specific definition. "Vaccine efficacy is the percentage reduction of disease in a vaccinated group of people compared to an unvaccinated group" So basically a 90% reduction in Covid infection.
At the time of writing (2020-11-09 12:04 UTC) the article uses "90% of people" and "90% protection" interchangeably. I assume it means "90% of individuals achieve immunity", rather than "individuals achieve 90% immunity". EDIT: See child comment re: Pfizer press release. EDIT 2: See [1] for said press release, which has more detailed information than the BBC article. [1] https://investors.pfizer.com/investor-news/pre…
- Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
- Analysis evaluated 94 confirmed cases of COVID-19 in trial participants
- Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected
- Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November
- Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints
Great news and the markets are reacting very positively to the news as well which indicates to me this could be the beginning of the end!
We have seen mutations due to minks recently which could make the vaccinations ineffective. These mutations might have been controlled but similar situations may arise in the next years.
For these reasons I am not entirely sure this is the beginning of the end.
At the time of writing (2020-11-09 12:04 UTC) the article uses "90% of people" and "90% protection" interchangeably. I assume it means "90% of individuals achieve immunity", rather than "individuals achieve 90% immunity". EDIT: See child comment re: Pfizer press release. EDIT 2: See [1] for said press release, which has more detailed information than the BBC article. [1] https://investors.pfizer.com/investor-news/pre…
First phrasing makes more sense than the second one to me -- what would it even mean for somebody to be "90% immune" to a disease?
At the time of writing (2020-11-09 12:04 UTC) the article uses "90% of people" and "90% protection" interchangeably. I assume it means "90% of individuals achieve immunity", rather than "individuals achieve 90% immunity". EDIT: See child comment re: Pfizer press release. EDIT 2: See [1] for said press release, which has more detailed information than the BBC article. [1] https://investors.pfizer.com/investor-news/pre…
First phrasing makes more sense than the second one to me -- what would it even mean for somebody to be "90% immune" to a disease?